Glycaemic Control of Type 2 Diabetics with Insulin Glargine in Everyday Practice Type 2 diabetic patients poorly controlled on insulin detemir therapy benefit from switching to insulin glargine
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F13%3A10294245" target="_blank" >RIV/00064203:_____/13:10294245 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11130/13:10294245
Výsledek na webu
—
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Glycaemic Control of Type 2 Diabetics with Insulin Glargine in Everyday Practice Type 2 diabetic patients poorly controlled on insulin detemir therapy benefit from switching to insulin glargine
Popis výsledku v původním jazyce
Background: In the RESOLUTE study, we investigated whether patients, with type 2 diabetes (T2D) inadequately controlled with insulin detemir (DET) in combination with oral anti-diabetic drugs (OADs) would benefit from switching to insulin glargine (GLA)(plus OADs) in everyday clinical practice. Methods: We performed this prospective, multinational, non-interventional, six-month observational study between June 2010 and November 2011. T2D patients with HbA(1c) > 7 to 10% (<53 to 86 mmol/mol) treated forat least three months with DET combined with OADs were documented after switching to GLA at the physician's discretion. The primary endpoint was the change in HbA(1c) after six months. Results: Of 564 T2D patients included in the study, 511 (61% female)were eligible for analysis (mean age: 61.9 +/- 10.1 years, BMI 30.9 +/- 5.1 kg/m(2), duration of diabetes 9.2 +/- 5.9 years). HbA(1c) decreased from 8.4 +/- 0.8% (61 10 mmol/mol) at baseline to 7.3 +/- 1.0% (56 +/- 11 mmol/mol) (p < 0.00
Název v anglickém jazyce
Glycaemic Control of Type 2 Diabetics with Insulin Glargine in Everyday Practice Type 2 diabetic patients poorly controlled on insulin detemir therapy benefit from switching to insulin glargine
Popis výsledku anglicky
Background: In the RESOLUTE study, we investigated whether patients, with type 2 diabetes (T2D) inadequately controlled with insulin detemir (DET) in combination with oral anti-diabetic drugs (OADs) would benefit from switching to insulin glargine (GLA)(plus OADs) in everyday clinical practice. Methods: We performed this prospective, multinational, non-interventional, six-month observational study between June 2010 and November 2011. T2D patients with HbA(1c) > 7 to 10% (<53 to 86 mmol/mol) treated forat least three months with DET combined with OADs were documented after switching to GLA at the physician's discretion. The primary endpoint was the change in HbA(1c) after six months. Results: Of 564 T2D patients included in the study, 511 (61% female)were eligible for analysis (mean age: 61.9 +/- 10.1 years, BMI 30.9 +/- 5.1 kg/m(2), duration of diabetes 9.2 +/- 5.9 years). HbA(1c) decreased from 8.4 +/- 0.8% (61 10 mmol/mol) at baseline to 7.3 +/- 1.0% (56 +/- 11 mmol/mol) (p < 0.00
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FB - Endokrinologie, diabetologie, metabolismus, výživa
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Diabetes, Stoffwechsel und Herz
ISSN
1861-7603
e-ISSN
—
Svazek periodika
22
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
DE - Spolková republika Německo
Počet stran výsledku
7
Strana od-do
141-147
Kód UT WoS článku
000344910400002
EID výsledku v databázi Scopus
—